FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam

(Reuters) – Gilead Sciences Inc’s experimental drug aimed at treating fatty liver disease NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another.

The trial was testing the drug, selonsertib, in patients with a form of fibrosis, called bridging, caused by NASH or Nonalcoholic Steatohepatitis.

The drug did not show an improvement in fibrosis symptoms, Gilead said.

The company in February said selonsertib had failed another trial testing patients with compensated cirrhosis, an advanced form of NASH.

Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as people